Vera Therapeutics Inc. (VERA)
Vera Therapeutics Statistics
Share Statistics
Vera Therapeutics has 63.77M shares outstanding. The number of shares has increased by 16.54% in one year.
| Shares Outstanding | 63.77M |
| Shares Change (YoY) | 16.54% |
| Shares Change (QoQ) | 0.67% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 48.96M |
| Failed to Deliver (FTD) Shares | 209 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 7.8M, so 12.23% of the outstanding shares have been sold short.
| Short Interest | 7.8M |
| Short % of Shares Out | 12.23% |
| Short % of Float | 15.93% |
| Short Ratio (days to cover) | 7.69 |
Valuation Ratios
The PE ratio is -15.38 and the forward PE ratio is -6.87. Vera Therapeutics's PEG ratio is -0.69.
| PE Ratio | -15.38 |
| Forward PE | -6.87 |
| PS Ratio | 0 |
| Forward PS | 1.8 |
| PB Ratio | 4.05 |
| P/FCF Ratio | -17.25 |
| PEG Ratio | -0.69 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Vera Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 25.67, with a Debt / Equity ratio of 0.09.
| Current Ratio | 25.67 |
| Quick Ratio | 25.67 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | -0.33 |
| Debt / FCF | -0.4 |
| Interest Coverage | 21.92 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.36M |
| Employee Count | 112 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -49.17% in the last 52 weeks. The beta is 1.27, so Vera Therapeutics's price volatility has been higher than the market average.
| Beta | 1.27 |
| 52-Week Price Change | -49.17% |
| 50-Day Moving Average | 27.84 |
| 200-Day Moving Average | 37.32 |
| Relative Strength Index (RSI) | 38.02 |
| Average Volume (20 Days) | 1.13M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -167.17M |
| Net Income | -152.15M |
| EBITDA | -167.17M |
| EBIT | -159.77M |
| Earnings Per Share (EPS) | -2.75 |
Balance Sheet
The company has 92.65M in cash and 54.64M in debt, giving a net cash position of 38.01M.
| Cash & Cash Equivalents | 92.65M |
| Total Debt | 54.64M |
| Net Cash | 38.01M |
| Retained Earnings | -461.25M |
| Total Assets | 655.68M |
| Working Capital | 625.85M |
Cash Flow
In the last 12 months, operating cash flow was -134.68M and capital expenditures -972K, giving a free cash flow of -135.65M.
| Operating Cash Flow | -134.68M |
| Capital Expenditures | -972K |
| Free Cash Flow | -135.65M |
| FCF Per Share | -2.45 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VERA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for VERA is $61, which is 181.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $61 |
| Price Target Difference | 181.9% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 10.03 |
| Piotroski F-Score | 2 |